Professor of Radiology Shahid Beheshti University of Medical Sciences
10.22034/icrj.2023.179099
Abstract
Tracer uptake pattern s in bone: Focal, multifocal, diffuse, and mixed
Diffuse marrow hyperplasia can be mimic marrow infiltration by myeloma
False-negative F-18 FDG PET/CT: High-dose steroid administration (within 10 days)
Compete F-18 FDG response before stem cell transplant associated with higher overall (92%) and event-free (89%) survival
Assessment of treatment response
Negative F-18 FDG PET 60 days following stem cell transplant associated with excellent prognosis
Persistent F-18 FDG activity following induction therapy associated with early relapse
Early identification of disease recurrence or progression
Patients with relapse often found to have new sites of disease on F-18 FDG PET/CT
Identification of target site for biopsy
F-18FDGPET/CT
Focal hypermetabolic lytic bone lesion or extramedullary site on F-18 FDG PET/CT
Bone (97%)
Diffuse marrow infiltration
Focal lytic bone lesions Breakout lesions: cortical disruption of osseous lesions
Useful for initial diagnosis and staging (55- 90% sensitivity) and restaging
Diffuse marrow uptake on F-18 FDG PET/ CT usually indicates elevated plasma cell papulation
Negative whole-body F-18 FDG PET/CT in patients with monoclonal gammopathy reliably identifies stable MGUS
Limited sensitivity in detecting diffuse bone marrow disease; MR more sensitive
More sensitive as compared to MR for EMD (96% sensitivity, 78% specificity)
Associated with advanced disease and poor prognosis
Clinically and radiographically detected in 10-16% of patients, at autopsy in 63% of patients
More common in younger patients
More aggressive myeloma types (nonsecretory myeloma, IgD myeloma, poorly differentiated), rapidly progressive, treatment resistant
Greater frequency with increasing duration if disease
Bakhshayeshkaram,, M. (2023). Hybrid Imaging Benign and Malignant MSK Tumors. Iranian Congress of Radiology, 38(1), 15-15. doi: 10.22034/icrj.2023.179099
MLA
Mehrdad Bakhshayeshkaram,. "Hybrid Imaging Benign and Malignant MSK Tumors". Iranian Congress of Radiology, 38, 1, 2023, 15-15. doi: 10.22034/icrj.2023.179099
HARVARD
Bakhshayeshkaram,, M. (2023). 'Hybrid Imaging Benign and Malignant MSK Tumors', Iranian Congress of Radiology, 38(1), pp. 15-15. doi: 10.22034/icrj.2023.179099
VANCOUVER
Bakhshayeshkaram,, M. Hybrid Imaging Benign and Malignant MSK Tumors. Iranian Congress of Radiology, 2023; 38(1): 15-15. doi: 10.22034/icrj.2023.179099